Skip to main content
Clinical Trials/NL-OMON51982
NL-OMON51982
Recruiting
Phase 3

International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia - Interfant-21

Prinses Máxima Centrum voor Kinderoncologie0 sites12 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Prinses Máxima Centrum voor Kinderoncologie
Enrollment
12
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Prinses Máxima Centrum voor Kinderoncologie

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients with newly diagnosed B\- precursor ALL or B\-cell MPAL according to
  • the WHO classification of tumours of haematopoietic and lymphoid tissues
  • (revised 4th edition 2017, with KMT2A\-rearrangement.
  • 2\. \<\= 365 days of age at the time of diagnosis of ALL.
  • 3\. Written informed consent of the parents or other legally authorized
  • guardian of the patient according to local law and regulations.

Exclusion Criteria

  • 1\. KMT2A\-germline patients.
  • 2\. T\-ALL.
  • 3\. Age \> 365 days at the time of diagnosis.
  • 4\. Relapsed ALL.
  • 5\. Treatment with systemic corticosteroids (equivalent prednisone \>10
  • mg/m2/day) for more than one week and/or any chemotherapeutic agent in the
  • 4\-week interval prior to diagnosis. Patients who received corticosteroids by
  • aerosol are eligible for the study.
  • Additional exclusion criteria for blinatumomab:
  • 1\. CD19 negative B\-precursor ALL at diagnosis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
'To assess the role of an early intensification of 2 AML induction blocks versus protocol Ib directly after induction in randomized MR & HR patients'acute lymphoblastic leukemia (including acute biphenotypic leukemia) in infants <1 year of ageMedDRA version: 14.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2005-004599-19-BEDutch Childhood Oncology Group445
Active, not recruiting
Phase 1
International collaborative treatment protocol for Infants under one year with Acute Lymphoblastic or Biphenotypic LeukemiaInfant Acute lymphoblastic leukemia (ALL) or biphenotypic leukemiaMedDRA version: 20.0Level: LLTClassification code 10067837Term: Acute biphenotypic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2005-004599-19-IEDutch Childhood Oncology Group445
Active, not recruiting
Phase 1
International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemiaacute lymphoblastic leukemia in children and adolescents 1 to <18 years of ageMedDRA version: 20.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864
EUCTR2007-004270-43-DEniversitätsklinikum Schleswig-Holstein, Campus Kiel4,950
Active, not recruiting
Phase 1
International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia - INTERFANT 06acute lymphoblastic leukemia (including acute biphenotypic leukemia) in infants <1 year of ageMedDRA version: 19.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864
EUCTR2005-004599-19-ATSt. Anna Kinderkrebsforschung450
Active, not recruiting
Phase 1
International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia - INTERFANT 06
EUCTR2005-004599-19-FRDutch Childhood Oncology Group450